An accumulation of evidence indicates that some malignant tumor, such as hematologic malignancies, can cause conventional therapy failure and cancer recurrence due to the characteristics of treatment resistance and self-regeneration. To date, CAR-T cells have demonstrated tremendous success in eliminating hematological malignancies, especially for CD19 positive CAR-T therapies in leukemias. Creative Biolabs, who always focus on the research highlight of onco-immunology studies, has successfully established an array of well-characterized Magic™ “humanized” animal models, which can provide humanized mouse models with CD19 positive patient-derived tumor xenografts for CAR-T evaluation.
CD19 - The Main CAR-T Therapy Target
Immunotherapy has been regarded the most promising novel cancer treatment approach in recent years. Among all the immunotherapies, chimeric antigen receptor T (CAR-T) therapies are one of the most concerns, especially for malignant tumors. Chimeric antigen receptor (CAR) T cells are engineered constructs composed of synthetic receptors that direct T cells to specific tumor surface antigens for subsequent elimination. Currently, treatments with chimeric antigen receptor-modified T (CAR-T) cells have shown successful clinical results in patients suffering hematologic malignancies, and the safety and feasibility of CAR-T therapies in solid tumors have been confirmed.
In the previous clinical trials from several institutions, CAR-T therapies in B cell malignancies including B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), and Hodgkin's lymphoma (HL) have indicated promising clinical outcomes by targeting CD19, CD20, or CD30, where mostly compelling success has been achieved in CD19-specific CAR-T cells for B-ALL with similar high complete remission (CR) rates of 70-94%. These studies indicated that CD19 is the main target for CAR-T therapies, especially in hematological malignancies, such as B cell lymphoma, chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).
Now Available in Creative Biolabs
As CAR-T therapies have rapidly developed into approved immuno-oncology agents, it is necessary to validate cost-effective efficacy and treatment security via in vivo preclinical models.
In Creative Biolabs, we provide two distinct well-established platforms for in vivo CAR-T evaluation system:
Utilizing CD19 Positive PDX to Evaluate CAR-T Therapies
Xenografts derived directly from patient tumor tissues, which have never been cultured in vitro or in contact with plastic, provide the most predictive xenograft model for preclinical drug evaluation. As a world leader in the industry of drug discovery, Creative Biolabs has created a Magic™ patient-derived xenograft (PDX) CAR-T therapy evaluation platform, which enables the rapid validation of models for efficacy testing, in highly predictive models that highly mimic human disease.
Why choose us?
We have established a large, diverse collection of numerous well-characterized CD19 positive PDX models, allowing access to a wide range of CAR-T targets. A team of senior scientists focused on humanized mouse models can support you to evaluate novel anti-tumor agents in a timely and cost-effective method. What's more, we also established comprehensive in vitro immunomodulation assessment service using various approaches. Please feel free to contact us for more details.
Creative Biolabs also offers other Humanized Mouse Based Tumor Models you may be interested in:
As we can offer a wide range of other common rodent tumor models, scientists in Creative Biolabs spare no effort to assist our clients in selecting the most appropriate one among the following:
For Research Use Only.
